CN108693352B - 新城疫病毒抗体检测试剂盒 - Google Patents
新城疫病毒抗体检测试剂盒 Download PDFInfo
- Publication number
- CN108693352B CN108693352B CN201810507579.9A CN201810507579A CN108693352B CN 108693352 B CN108693352 B CN 108693352B CN 201810507579 A CN201810507579 A CN 201810507579A CN 108693352 B CN108693352 B CN 108693352B
- Authority
- CN
- China
- Prior art keywords
- seq
- newcastle disease
- disease virus
- kit
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 241000711404 Avian avulavirus 1 Species 0.000 title claims abstract description 43
- 238000001514 detection method Methods 0.000 title abstract description 35
- 229920001184 polypeptide Polymers 0.000 claims abstract description 60
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 59
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 59
- 239000012472 biological sample Substances 0.000 claims description 21
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 10
- 208000010359 Newcastle Disease Diseases 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 210000002966 serum Anatomy 0.000 claims description 10
- 241000287828 Gallus gallus Species 0.000 claims description 7
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 210000002381 plasma Anatomy 0.000 claims description 5
- 229960005486 vaccine Drugs 0.000 claims description 3
- 239000007787 solid Substances 0.000 abstract description 14
- 230000035945 sensitivity Effects 0.000 description 22
- 238000000034 method Methods 0.000 description 20
- 238000002965 ELISA Methods 0.000 description 13
- 239000000523 sample Substances 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 11
- 241000700605 Viruses Species 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 238000010211 hemagglutination inhibition (HI) assay Methods 0.000 description 7
- 239000007788 liquid Substances 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 101710133291 Hemagglutinin-neuraminidase Proteins 0.000 description 5
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241000271566 Aves Species 0.000 description 3
- 101710181008 P protein Proteins 0.000 description 3
- 101710177166 Phosphoprotein Proteins 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 description 2
- 102000005348 Neuraminidase Human genes 0.000 description 2
- 108010006232 Neuraminidase Proteins 0.000 description 2
- 102100034574 P protein Human genes 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000012470 diluted sample Substances 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001018 virulence Effects 0.000 description 2
- DCVYRWFAMZFSDA-ZLUOBGJFSA-N Ala-Ser-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O DCVYRWFAMZFSDA-ZLUOBGJFSA-N 0.000 description 1
- YWENWUYXQUWRHQ-LPEHRKFASA-N Arg-Cys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CS)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O YWENWUYXQUWRHQ-LPEHRKFASA-N 0.000 description 1
- RWDVGVPHEWOZMO-GUBZILKMSA-N Arg-Cys-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCNC(N)=N)C(O)=O RWDVGVPHEWOZMO-GUBZILKMSA-N 0.000 description 1
- VCJCPARXDBEGNE-GUBZILKMSA-N Asn-Pro-Pro Chemical compound NC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 VCJCPARXDBEGNE-GUBZILKMSA-N 0.000 description 1
- KYQJHBWHRASMKG-ZLUOBGJFSA-N Asn-Ser-Cys Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(O)=O KYQJHBWHRASMKG-ZLUOBGJFSA-N 0.000 description 1
- 241000035315 Avulavirus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- LBSKYJOZIIOZIO-DCAQKATOSA-N Cys-Lys-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CS)N LBSKYJOZIIOZIO-DCAQKATOSA-N 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- QXPRJQPCFXMCIY-NKWVEPMBSA-N Gly-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN QXPRJQPCFXMCIY-NKWVEPMBSA-N 0.000 description 1
- GMTXWRIDLGTVFC-IUCAKERBSA-N Gly-Lys-Glu Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O GMTXWRIDLGTVFC-IUCAKERBSA-N 0.000 description 1
- VNNRLUNBJSWZPF-ZKWXMUAHSA-N Gly-Ser-Ile Chemical compound [H]NCC(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O VNNRLUNBJSWZPF-ZKWXMUAHSA-N 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- LQSBBHNVAVNZSX-GHCJXIJMSA-N Ile-Ala-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)N)C(=O)O)N LQSBBHNVAVNZSX-GHCJXIJMSA-N 0.000 description 1
- CDGLBYSAZFIIJO-RCOVLWMOSA-N Ile-Gly-Gly Chemical compound CC[C@H](C)[C@H]([NH3+])C(=O)NCC(=O)NCC([O-])=O CDGLBYSAZFIIJO-RCOVLWMOSA-N 0.000 description 1
- UQXADIGYEYBJEI-DJFWLOJKSA-N Ile-His-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC(=O)O)C(=O)O)N UQXADIGYEYBJEI-DJFWLOJKSA-N 0.000 description 1
- PFPUFNLHBXKPHY-HTFCKZLJSA-N Ile-Ile-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)O)N PFPUFNLHBXKPHY-HTFCKZLJSA-N 0.000 description 1
- 101710085938 Matrix protein Proteins 0.000 description 1
- 101710127721 Membrane protein Proteins 0.000 description 1
- 206010061298 Mucosal haemorrhage Diseases 0.000 description 1
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
- 241000711504 Paramyxoviridae Species 0.000 description 1
- DEDANIDYQAPTFI-IHRRRGAJSA-N Pro-Asp-Tyr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O DEDANIDYQAPTFI-IHRRRGAJSA-N 0.000 description 1
- DIZLUAZLNDFDPR-CIUDSAMLSA-N Pro-Cys-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CS)NC(=O)[C@@H]1CCCN1 DIZLUAZLNDFDPR-CIUDSAMLSA-N 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- CXBFHZLODKPIJY-AAEUAGOBSA-N Ser-Gly-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CO)N CXBFHZLODKPIJY-AAEUAGOBSA-N 0.000 description 1
- TZQWJCGVCIJDMU-HEIBUPTGSA-N Thr-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)O)N)O TZQWJCGVCIJDMU-HEIBUPTGSA-N 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 230000010530 Virus Neutralization Effects 0.000 description 1
- 238000012459 agar diffusion assay Methods 0.000 description 1
- 238000007818 agglutination assay Methods 0.000 description 1
- 108010093581 aspartyl-proline Proteins 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 108010029020 prolylglycine Proteins 0.000 description 1
- 108010015796 prolylisoleucine Proteins 0.000 description 1
- 230000007026 protein scission Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810507579.9A CN108693352B (zh) | 2018-05-24 | 2018-05-24 | 新城疫病毒抗体检测试剂盒 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810507579.9A CN108693352B (zh) | 2018-05-24 | 2018-05-24 | 新城疫病毒抗体检测试剂盒 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108693352A CN108693352A (zh) | 2018-10-23 |
CN108693352B true CN108693352B (zh) | 2020-05-01 |
Family
ID=63847911
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810507579.9A Expired - Fee Related CN108693352B (zh) | 2018-05-24 | 2018-05-24 | 新城疫病毒抗体检测试剂盒 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108693352B (zh) |
-
2018
- 2018-05-24 CN CN201810507579.9A patent/CN108693352B/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN108693352A (zh) | 2018-10-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3584990B2 (ja) | 抗ヒトインフルエンザウイルス抗体 | |
JP5849065B2 (ja) | A型インフルエンザウイルスh5亜型の検出法 | |
JP5432453B2 (ja) | A型インフルエンザウイルス強毒株の検出法 | |
JP5827701B2 (ja) | インフルエンザウイルスh5亜型の免疫検出法 | |
JP5435844B2 (ja) | インフルエンザウイルスh5亜型の免疫検出法 | |
CN108761077A (zh) | 禽病毒病蛋白芯片抗体检测试剂盒及其制备方法和应用 | |
CN111751553A (zh) | 小反刍兽疫病毒H蛋白抗体iELISA检测方法及应用 | |
CN108956986B (zh) | 新城疫病毒抗体检测试剂盒 | |
CN108727478B (zh) | 一种ibv特异性多肽抗原、抗体、elisa检测试剂盒及其应用 | |
CN108693352B (zh) | 新城疫病毒抗体检测试剂盒 | |
CN115112885B (zh) | 一种hpv检测试剂盒及其制备方法和应用 | |
CN110531079B (zh) | 新城疫病毒抗体检测试剂盒 | |
CN110531081B (zh) | 新城疫病毒抗体检测试剂盒 | |
CN110531080B (zh) | 新城疫病毒抗体检测试剂盒 | |
CN108717124A (zh) | 新城疫病毒抗体检测试剂盒 | |
CN110498844B (zh) | 小反刍兽疫诊断试剂盒 | |
CN110488017B (zh) | 新城疫病毒抗体检测试剂盒 | |
CN110488010B (zh) | 新城疫病毒抗体检测试剂盒 | |
CN110488011B (zh) | 新城疫病毒抗体检测试剂盒 | |
CN110498845B (zh) | 小反刍兽疫诊断试剂盒 | |
CN111537736A (zh) | 一种鸡毒支原体抗体的间接elisa检测试剂盒及检测方法 | |
CN111995666A (zh) | 用于检测微生物的干扰肽和方法 | |
US8809004B2 (en) | Detection of feline immunodeficiency virus | |
CN114230642B (zh) | 一种区分h7n9亚型禽流感病毒感染与免疫动物的多肽及检测方法 | |
CN116519944B (zh) | 一种鸡新城疫病毒抗体间接elisa检测方法及其试剂盒 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20191217 Address after: 215123 unit 11, floor 5, building 24, No. 388, Xinping street, Suzhou Industrial Park, Suzhou City, Jiangsu Province Applicant after: Suzhou Youdi Biotechnology Co.,Ltd. Address before: 215123 A4 building, bio nano Park, 218 Xing Hu Street, Suzhou Industrial Park, Suzhou, Jiangsu. Applicant before: SUZHOU EPITOPE BIOTECH INC. |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20200325 Address after: 215123 Suzhou Jiangsu Industrial Park, No., No. 398, building D, No. 11 Applicant after: SUZHOU INDUSTRIAL PARK QIANGDONG PHARMACEUTICAL TECHNOLOGY Co.,Ltd. Applicant after: Suzhou Youdi Biotechnology Co.,Ltd. Address before: 215123 unit 11, floor 5, building 24, No. 388, Xinping street, Suzhou Industrial Park, Suzhou City, Jiangsu Province Applicant before: Suzhou Youdi Biotechnology Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20200501 |
|
CF01 | Termination of patent right due to non-payment of annual fee |